董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Luo | 男 | Co-Founder, Chief Executive Officer and Chairman of the Board | 57 | 未披露 | 1154.75 | 2022-11-21 |
| Cuong Do | 男 | Independent Director | 57 | 未披露 | 未持股 | 2022-11-21 |
| Lefei SUN | 男 | Director | 43 | 未披露 | 未持股 | 2022-11-21 |
| Man Kin Tam | 男 | Chief Financial Officer and Director | 45 | 未披露 | 未持股 | 2022-11-21 |
| Andy Cheung | 男 | Independent Director | 63 | 未披露 | 未持股 | 2022-11-21 |
| Min Li | 男 | Independent Director | 60 | 未披露 | 未持股 | 2022-11-21 |
| Yuwen Liu | 女 | Independent Director | -- | 未披露 | 未持股 | 2022-11-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Luo | 男 | Co-Founder, Chief Executive Officer and Chairman of the Board | 57 | 未披露 | 1154.75 | 2022-11-21 |
| Fangyong Du | 男 | Chief Technology Officer | 53 | 未披露 | 123.52 | 2022-11-21 |
| JC Xu | 女 | Chief Scientific Officer | 58 | 未披露 | 未持股 | 2022-11-21 |
| Qinghai Zhao | 男 | Chief Manufacturing Officer | 62 | 未披露 | 未持股 | 2022-11-21 |
| Man Kin Tam | 男 | Chief Financial Officer and Director | 45 | 未披露 | 未持股 | 2022-11-21 |
| Yu Ren | 男 | Chief Strategy and Corporate Development Officer | 48 | 未披露 | 未持股 | 2022-11-21 |
| Chunfang Gu | 女 | Senior Director of Finance | -- | 未披露 | 未持股 | 2022-11-21 |
| Ling Zhou | 女 | Senior Director of Human Resources | -- | 未披露 | 未持股 | 2022-11-21 |
董事简历
中英对照 | 中文 | 英文- Peter Luo
-
Peter Luo是天演药业的联合创始人，自2011年11月起担任天演药业的首席执行官，自2018年2月起担任董事会主席。Luo博士于1998年7月至2000年8月在Xencor（Nasdaq：XNCR）担任计算蛋白质设计和蛋白质实验室的第一位首席科学家。2000年9月Luo博士创立了Abmaxis Inc.，并担任其联合创始人、首席技术官、总裁和董事，2006年5月Luo博士领导默克制药公司（NYSE：MRK）收购了Abmaxis Inc.，之后Luo博士在默克担任生物技术总监，并在整个职业生涯中担任默克制药子公司Abmaxis的首席技术官，Luo博士还领导了与多个全球合作伙伴的合作和战略伙伴关系方面的业务发展努力，Luo博士于1986年获得北京大学技术物理应用化学学士学位，1989年获得中国科学院高能物理研究所应用物理硕士学位，1995年获得芝加哥大学化学博士学位。Luo博士还于1998年在斯坦福大学完成了蛋白质折叠方面的博士后研究。Luo博士的配偶是Xiaohong（Kristine）她是天演药业的高级副总裁，临床运营负责人。
Peter Luo is Adagene Inc. Co-Founder and has served as Adagene Inc. Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor Nasdaq: XNCR from July 1998 to August 2000. In September 2000 Dr. Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006 Dr. Luo led the acquisition of Abmaxis Inc. by Merck & Co. NYSE: MRK, after which Dr. Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr. Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr. Luo received his bachelor's degree in applied chemistry in technical physics from Peking University in 1986 master's degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989 and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998. Dr. Luo's spouse is Xiaohong Kristine She who is Adagene Inc. Senior Vice President, Head of Clinical Operations. - Peter Luo是天演药业的联合创始人，自2011年11月起担任天演药业的首席执行官，自2018年2月起担任董事会主席。Luo博士于1998年7月至2000年8月在Xencor（Nasdaq：XNCR）担任计算蛋白质设计和蛋白质实验室的第一位首席科学家。2000年9月Luo博士创立了Abmaxis Inc.，并担任其联合创始人、首席技术官、总裁和董事，2006年5月Luo博士领导默克制药公司（NYSE：MRK）收购了Abmaxis Inc.，之后Luo博士在默克担任生物技术总监，并在整个职业生涯中担任默克制药子公司Abmaxis的首席技术官，Luo博士还领导了与多个全球合作伙伴的合作和战略伙伴关系方面的业务发展努力，Luo博士于1986年获得北京大学技术物理应用化学学士学位，1989年获得中国科学院高能物理研究所应用物理硕士学位，1995年获得芝加哥大学化学博士学位。Luo博士还于1998年在斯坦福大学完成了蛋白质折叠方面的博士后研究。Luo博士的配偶是Xiaohong（Kristine）她是天演药业的高级副总裁，临床运营负责人。
- Peter Luo is Adagene Inc. Co-Founder and has served as Adagene Inc. Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor Nasdaq: XNCR from July 1998 to August 2000. In September 2000 Dr. Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006 Dr. Luo led the acquisition of Abmaxis Inc. by Merck & Co. NYSE: MRK, after which Dr. Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr. Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr. Luo received his bachelor's degree in applied chemistry in technical physics from Peking University in 1986 master's degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989 and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998. Dr. Luo's spouse is Xiaohong Kristine She who is Adagene Inc. Senior Vice President, Head of Clinical Operations.
- Cuong Do
-
Cuong Do自2016年起担任董事，自2021年4月起担任总裁兼首席执行官。Do先生于2015年2月至2020年12月在三星担任全球战略小组主席。Do先生帮助制定了三星集团多元化业务组合的战略方向。他曾于2011年10月至2014年3月担任Merck首席战略官，2009年6月至2011年10月担任泰科电子公司首席战略官，2007年12月至2009年3月担任联想公司首席战略官。Do先生是麦肯锡公司的前高级合伙人，在McKinsey & Company工作了17年，帮助建立了医疗保健、高科技和企业融资业务。他拥有达特茅斯学院的学士学位和达特茅斯大学塔克商学院的MBA学位。
Cuong Do has served as a director since 2016 and as President and CEO since April 2021. Mr. Do was the President, Global Strategy Group, at Samsung from February 2015 to December 2020. Mr. Do helped set the strategic direction for Samsung Group's diverse business portfolio. He was previously the Chief Strategy Officer for Merck from October 2011 to March 2014 and Tyco Electronics from June 2009 to October 2011 and Lenovo from December 2007 to March 2009. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years and helped build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth. - Cuong Do自2016年起担任董事，自2021年4月起担任总裁兼首席执行官。Do先生于2015年2月至2020年12月在三星担任全球战略小组主席。Do先生帮助制定了三星集团多元化业务组合的战略方向。他曾于2011年10月至2014年3月担任Merck首席战略官，2009年6月至2011年10月担任泰科电子公司首席战略官，2007年12月至2009年3月担任联想公司首席战略官。Do先生是麦肯锡公司的前高级合伙人，在McKinsey & Company工作了17年，帮助建立了医疗保健、高科技和企业融资业务。他拥有达特茅斯学院的学士学位和达特茅斯大学塔克商学院的MBA学位。
- Cuong Do has served as a director since 2016 and as President and CEO since April 2021. Mr. Do was the President, Global Strategy Group, at Samsung from February 2015 to December 2020. Mr. Do helped set the strategic direction for Samsung Group's diverse business portfolio. He was previously the Chief Strategy Officer for Merck from October 2011 to March 2014 and Tyco Electronics from June 2009 to October 2011 and Lenovo from December 2007 to March 2009. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years and helped build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.
- Lefei SUN
-
Lefei Sun自2019年12月起担任天演药业的董事。Sun先生自2018年11月起担任香港亚洲医疗控股有限公司非执行董事，香港亚洲医疗控股有限公司为亚洲领先的医院管理集团，拥有武汉亚洲心脏医院等医院资产。他也是Ocumension Therapeutics（HKEX：1477）和Canbridge Pharmaceuticals Inc.等多家生物科技公司的非执行董事，Sun先生自2018年5月起在通用大西洋担任中国医疗保健主管，自2020年1月起担任董事总经理，负责医疗保健和生命科学领域的私募股权投资和投资组合管理，2014年12月至2018年4月，Sun先生是北京华泰瑞和投资基金管理公司（LLP），又名华泰医疗保健投资基金的创始合伙人和投资委员会成员。在加入通用大西洋之前，Sun先生曾在弘毅投资、瑞士信贷、OrbiMed、兰花亚洲担任多个投资角色，并在麦肯锡公司担任管理顾问，均在医疗保健领域，Sun先生于2006年在约翰霍普金斯大学医学院获得神经科学硕士学位，2002年在清华大学获得数理学士学位。
Lefei SUN,has been a non-executive director of Hutchmed (China) Limited since 2022. He is also a member of Hutchmed (China) Limited technical committee. He has been the managing director and head of China healthcare for General Atlantic since 2018, in charge of private equity investment and portfolio management in healthcare and life sciences sectors. Before joining General Atlantic, Mr. Sun was the founding partner of Huatai Healthcare Investment Fund, successfully leading the investment in Mindray Medical, which is listed on Shenzhen Stock Exchange. Mr. Sun is also a director of Adagene nc. and Genesis MedTech Group Inc. He was formerly a director of CANbridge Pharmaceuticals nc. and Ocumension Therapeutics nc. Mr. Sun holds a bachelor of science degree in mathematics and physics from Tsinghua University. He also holds a master of arts degree in neuroscience from the Johns Hopkins University. - Lefei Sun自2019年12月起担任天演药业的董事。Sun先生自2018年11月起担任香港亚洲医疗控股有限公司非执行董事，香港亚洲医疗控股有限公司为亚洲领先的医院管理集团，拥有武汉亚洲心脏医院等医院资产。他也是Ocumension Therapeutics（HKEX：1477）和Canbridge Pharmaceuticals Inc.等多家生物科技公司的非执行董事，Sun先生自2018年5月起在通用大西洋担任中国医疗保健主管，自2020年1月起担任董事总经理，负责医疗保健和生命科学领域的私募股权投资和投资组合管理，2014年12月至2018年4月，Sun先生是北京华泰瑞和投资基金管理公司（LLP），又名华泰医疗保健投资基金的创始合伙人和投资委员会成员。在加入通用大西洋之前，Sun先生曾在弘毅投资、瑞士信贷、OrbiMed、兰花亚洲担任多个投资角色，并在麦肯锡公司担任管理顾问，均在医疗保健领域，Sun先生于2006年在约翰霍普金斯大学医学院获得神经科学硕士学位，2002年在清华大学获得数理学士学位。
- Lefei SUN,has been a non-executive director of Hutchmed (China) Limited since 2022. He is also a member of Hutchmed (China) Limited technical committee. He has been the managing director and head of China healthcare for General Atlantic since 2018, in charge of private equity investment and portfolio management in healthcare and life sciences sectors. Before joining General Atlantic, Mr. Sun was the founding partner of Huatai Healthcare Investment Fund, successfully leading the investment in Mindray Medical, which is listed on Shenzhen Stock Exchange. Mr. Sun is also a director of Adagene nc. and Genesis MedTech Group Inc. He was formerly a director of CANbridge Pharmaceuticals nc. and Ocumension Therapeutics nc. Mr. Sun holds a bachelor of science degree in mathematics and physics from Tsinghua University. He also holds a master of arts degree in neuroscience from the Johns Hopkins University.
- Man Kin Tam
-
Man Kin Tam自2019年9月起担任天演药业的首席财务官，并将在天演药业有关F-1表格的注册声明生效后立即担任天演药业的董事。Man Kin Tam先生在亚太地区拥有超过20年的金融和银行业管理经验，Man Kin Tam先生于1999年至2010年在汇丰银行和摩根大通银行（N.A。）工作。Tam先生于2010年4月至2015年10月期间担任Mineralogy Pty Limited项目总监及Resourcehouse Limited财务总监。2015年10月至2019年8月，Tam先生连续担任中国再生医学国际有限公司（港交所：8158），Beijing Gas Blue Sky Holdings Limited（港交所代码：6828），Agentus Therapeutics，Inc.的首席财务官，Tam先生为澳洲会计师公会会员，美国会计师公会及香港会计师公会会员，亦为CFA及FRM特许持有人。他于1997年在奥克兰大学获得土木与资源工程学士学位，2001年在莫纳什大学获得会计学硕士学位，2005年在西安大略大学获得工商管理硕士学位。
Man Kin Tam has served as our Chief Financial Officer since September 2019 and our director since February 2021. Mr. Tam has over 20 years of management experience in finance and banking across the Asia-Pacific region. Mr. Tam worked in HSBC and J.P. Morgan Chase Bank, N.A. from 1999 to 2010. Mr. Tam served as project director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited from April 2010 to October 2015. From October 2015 to August 2019 Mr. Tam consecutively served as the Chief Financial Officer of China Regenerative Medicine International Limited HKEx: 8158 Beijing Gas Blue Sky Holdings Limited HKEx: 6828 and AgenTus Therapeutics, Inc. Mr. Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder. He received his bachelor's degree in civil & resources engineering from the University of Auckland in 1997 master's degree in practising accounting from Monash University in 2001 and an Executive Master of Business Administration degree from the University of Western Ontario in 2005. - Man Kin Tam自2019年9月起担任天演药业的首席财务官，并将在天演药业有关F-1表格的注册声明生效后立即担任天演药业的董事。Man Kin Tam先生在亚太地区拥有超过20年的金融和银行业管理经验，Man Kin Tam先生于1999年至2010年在汇丰银行和摩根大通银行（N.A。）工作。Tam先生于2010年4月至2015年10月期间担任Mineralogy Pty Limited项目总监及Resourcehouse Limited财务总监。2015年10月至2019年8月，Tam先生连续担任中国再生医学国际有限公司（港交所：8158），Beijing Gas Blue Sky Holdings Limited（港交所代码：6828），Agentus Therapeutics，Inc.的首席财务官，Tam先生为澳洲会计师公会会员，美国会计师公会及香港会计师公会会员，亦为CFA及FRM特许持有人。他于1997年在奥克兰大学获得土木与资源工程学士学位，2001年在莫纳什大学获得会计学硕士学位，2005年在西安大略大学获得工商管理硕士学位。
- Man Kin Tam has served as our Chief Financial Officer since September 2019 and our director since February 2021. Mr. Tam has over 20 years of management experience in finance and banking across the Asia-Pacific region. Mr. Tam worked in HSBC and J.P. Morgan Chase Bank, N.A. from 1999 to 2010. Mr. Tam served as project director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited from April 2010 to October 2015. From October 2015 to August 2019 Mr. Tam consecutively served as the Chief Financial Officer of China Regenerative Medicine International Limited HKEx: 8158 Beijing Gas Blue Sky Holdings Limited HKEx: 6828 and AgenTus Therapeutics, Inc. Mr. Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder. He received his bachelor's degree in civil & resources engineering from the University of Auckland in 1997 master's degree in practising accounting from Monash University in 2001 and an Executive Master of Business Administration degree from the University of Western Ontario in 2005.
- Andy Cheung
-
Andy Cheung自2021年2月起担任天演药业独立董事。Cheung先生于2018年7月至2020年6月担任安永（Ernst&Young）“EY”亚太区副区域管理合伙人，负责监管业务运营、财务、信息技术和风险管理职能。Cheung先生于2013年7月至2018年6月担任安永在大中华区的鉴证主管。Cheung先生曾担任JW（Cayman）Therapeutics Co.Ltd.的独立非执行董事（香港交易所：2126）从2020年10月开始。Cheung先生于一九八二年六月获英国兰开斯特大学会计学及金融学士学位。1983年8月获英国伦敦经济学院会计学和金融学硕士学位。Cheung先生是香港注册会计师协会会员。
Andy Cheung has served as our independent director since February 2021. Mr. Cheung has many years of auditing and accounting professional experience. Mr. Cheung was deputy area managing partner of Ernst & Young “EY” in Asia Pacific overseeing the business operations, finance, information technology and risk management functions from July 2018 to June 2020. Mr. Cheung was the assurance leader for EY in Greater China from July 2013 to June 2018. Mr. Cheung has served as an independent non-executive director of JW Cayman Therapeutics Co. Ltd HKEX:2126 since October 2020. Mr. Cheung received his bachelor's degree in accounting and finance from the University of Lancaster in the United Kingdom in July 1982. He obtained a master's degree in accounting and finance from London School of Economics and Political Science in the United Kingdom in August 1983. Mr. Cheung is a member of Hong Kong Institute of Certified Public Accountants. - Andy Cheung自2021年2月起担任天演药业独立董事。Cheung先生于2018年7月至2020年6月担任安永（Ernst&Young）“EY”亚太区副区域管理合伙人，负责监管业务运营、财务、信息技术和风险管理职能。Cheung先生于2013年7月至2018年6月担任安永在大中华区的鉴证主管。Cheung先生曾担任JW（Cayman）Therapeutics Co.Ltd.的独立非执行董事（香港交易所：2126）从2020年10月开始。Cheung先生于一九八二年六月获英国兰开斯特大学会计学及金融学士学位。1983年8月获英国伦敦经济学院会计学和金融学硕士学位。Cheung先生是香港注册会计师协会会员。
- Andy Cheung has served as our independent director since February 2021. Mr. Cheung has many years of auditing and accounting professional experience. Mr. Cheung was deputy area managing partner of Ernst & Young “EY” in Asia Pacific overseeing the business operations, finance, information technology and risk management functions from July 2018 to June 2020. Mr. Cheung was the assurance leader for EY in Greater China from July 2013 to June 2018. Mr. Cheung has served as an independent non-executive director of JW Cayman Therapeutics Co. Ltd HKEX:2126 since October 2020. Mr. Cheung received his bachelor's degree in accounting and finance from the University of Lancaster in the United Kingdom in July 1982. He obtained a master's degree in accounting and finance from London School of Economics and Political Science in the United Kingdom in August 1983. Mr. Cheung is a member of Hong Kong Institute of Certified Public Accountants.
- Min Li
-
Min Li自2021年2月起担任天演药业独立董事。Min Li博士是SciNeuro Pharmaceuticals的创始人、首席执行官和董事。SciNeuro Pharmaceuticals是一家总部位于上海的生物技术公司，致力于开发针对中枢神经系统疾病的创新疗法。Li博士曾于2013年至2019年担任葛兰素史克公司高级副总裁、全球神经科学研发主管。在葛兰素史克任职期间，他还担任过葛兰素史克中国研发部总经理，这是国家一级的最高级别官员。在进入这个行业之前，Li博士在约翰霍普金斯大学医学院担任了20多年的神经科学终身教授。Li博士服务于科学咨询委员会，非营利组织和公司董事会，包括跨国公司康宁、辉瑞和默克、疾病基金会（RYR基金会、AHA）和生物技术公司（XeCOR、AffyMax、DATAVANT、ICAGEN和CODA生物技术）。他还是约翰霍普金斯医学院的神经科学副教授。1984年获武汉大学生物化学学士学位，1990年获美国约翰霍普金斯大学分子免疫学博士学位。作为海伦海惠特尼研究员，他在加州大学旧金山分校进行博士后研究。1994年，他获得斯隆奖，回到约翰霍普金斯大学，成为埃丝特a&约瑟夫克林根斯坦神经科学研究员。李博士发表了120多篇科学论文，拥有生物技术专利。他的研究和奖学金获得了国际认可，包括美国科学促进协会（American Association for Advanced of Science）和美国心脏协会（American Heart Association）的资深研究员。
Min Li has served as Adagene Inc.'s independent director since February 2021. Dr. Min Li is the founder, CEO and director of SciNeuro Pharmaceuticals, a biotechnology company headquartered in Shanghai focused on developing innovative therapeutics for CNS diseases. Dr. Li was formerly Senior Vice President, Global Head of Neuroscience R&D at GSK from 2013 to 2019. During his employment with GSK, he also served as General Manager of GSK R&D China, the highest-ranking officer at the country level. Before moving into industry, Dr. Li had served as a tenured Professor of Neuroscience at Johns Hopkins University School of Medicine for over 20 years. Dr. Li served on scientific advisory boards, non-profit and corporate boards that include multinational corporations Corning, Pfizer and Merck, disease foundations RYR-foundation, AHA and biotech companies Xencor, Affymax, Datavant, Icagen, and Coda Biotechnologies. He is also an Adjunct Professor of Neuroscience at Johns Hopkins School of Medicine. Dr. Li received his B.S. degree in biochemistry from Wuhan University in 1984 and his Ph.D. in molecular immunology from Johns Hopkins University in 1990. As a Helen Hay Whitney Fellow, he performed postdoctoral research at University of California San Francisco. With a Sloan Award, in 1994 he returned to Johns Hopkins to join the faculty as an Esther A & Joseph Klingenstein Neuroscience Fellow. Dr. Li has published more than 120 scientific articles and holds patents in biotechnologies. His research and scholarship were recognized internationally with awards including being a fellow of American Association for Advancement of Science and an established fellow of American Heart Association. - Min Li自2021年2月起担任天演药业独立董事。Min Li博士是SciNeuro Pharmaceuticals的创始人、首席执行官和董事。SciNeuro Pharmaceuticals是一家总部位于上海的生物技术公司，致力于开发针对中枢神经系统疾病的创新疗法。Li博士曾于2013年至2019年担任葛兰素史克公司高级副总裁、全球神经科学研发主管。在葛兰素史克任职期间，他还担任过葛兰素史克中国研发部总经理，这是国家一级的最高级别官员。在进入这个行业之前，Li博士在约翰霍普金斯大学医学院担任了20多年的神经科学终身教授。Li博士服务于科学咨询委员会，非营利组织和公司董事会，包括跨国公司康宁、辉瑞和默克、疾病基金会（RYR基金会、AHA）和生物技术公司（XeCOR、AffyMax、DATAVANT、ICAGEN和CODA生物技术）。他还是约翰霍普金斯医学院的神经科学副教授。1984年获武汉大学生物化学学士学位，1990年获美国约翰霍普金斯大学分子免疫学博士学位。作为海伦海惠特尼研究员，他在加州大学旧金山分校进行博士后研究。1994年，他获得斯隆奖，回到约翰霍普金斯大学，成为埃丝特a&约瑟夫克林根斯坦神经科学研究员。李博士发表了120多篇科学论文，拥有生物技术专利。他的研究和奖学金获得了国际认可，包括美国科学促进协会（American Association for Advanced of Science）和美国心脏协会（American Heart Association）的资深研究员。
- Min Li has served as Adagene Inc.'s independent director since February 2021. Dr. Min Li is the founder, CEO and director of SciNeuro Pharmaceuticals, a biotechnology company headquartered in Shanghai focused on developing innovative therapeutics for CNS diseases. Dr. Li was formerly Senior Vice President, Global Head of Neuroscience R&D at GSK from 2013 to 2019. During his employment with GSK, he also served as General Manager of GSK R&D China, the highest-ranking officer at the country level. Before moving into industry, Dr. Li had served as a tenured Professor of Neuroscience at Johns Hopkins University School of Medicine for over 20 years. Dr. Li served on scientific advisory boards, non-profit and corporate boards that include multinational corporations Corning, Pfizer and Merck, disease foundations RYR-foundation, AHA and biotech companies Xencor, Affymax, Datavant, Icagen, and Coda Biotechnologies. He is also an Adjunct Professor of Neuroscience at Johns Hopkins School of Medicine. Dr. Li received his B.S. degree in biochemistry from Wuhan University in 1984 and his Ph.D. in molecular immunology from Johns Hopkins University in 1990. As a Helen Hay Whitney Fellow, he performed postdoctoral research at University of California San Francisco. With a Sloan Award, in 1994 he returned to Johns Hopkins to join the faculty as an Esther A & Joseph Klingenstein Neuroscience Fellow. Dr. Li has published more than 120 scientific articles and holds patents in biotechnologies. His research and scholarship were recognized internationally with awards including being a fellow of American Association for Advancement of Science and an established fellow of American Heart Association.
- Yuwen Liu
-
Yuwen Liu 自2022年2月起担任Adagene Inc.的独立董事。Yuwen Liu 女士是生物技术、生物制药和医疗技术行业的主要倡导者，曾担任企业家、顾问和投资者20多年。2010年至2014年，Yuwen Liu 女士担任苏州工业园区生物技术发展有限公司BioBAY的董事长兼首席执行官，之后担任执行董事，将其打造成发展最快的生物技术集群之一，服务于400多家初创企业，包括BrightGene、Innovent和苏州桥根，她还在董事会任职。在此之前，Yuwen Liu 女士自2005年起在BioBay担任过多个职位。作为创新的坚定支持者，她还是博和天使基金的创始合伙人。博和天使基金是中国首批专注于医疗保健初创企业的天使基金之一，投资于生物制品、药物发现和诊断。Yuwen Liu 女士还是生物风险基金投资委员会的创始主席。Yuwen Liu 女士曾担任Perrigo在中国设立业务的首位首席代表。在职业生涯早期，她曾在华纳兰伯特旗下的Capsugel公司担任质量和业务发展方面的多个职位，后来被辉瑞收购。Yuwen Liu 女士于1997年毕业于中国药科大学，获得药剂学硕士学位，并于2004年在复旦大学和挪威管理学院获得管理硕士学位。她是一名持证药剂师。
Yuwen Liu has served as our independent director since February 2022. Ms. Liu is a leading advocate for the biotechnology, biopharmaceutical and medical technology industries, with over 20 years as an entrepreneur, advisor and investor. From 2010 to 2014 Ms. Liu was Chair and CEO, followed by executive director, of Suzhou Industrial Park Biotech Development Co. Ltd. BioBAY, building it into one of the fastest growing biotech clusters serving over 400 start-ups, including BrightGene, Innovent, and Qiagen Suzhou, where she also served on the boards of directors. Prior to that, Ms. Liu served various positions at BioBay since 2005. As a strong supporter of innovation, she was also a founding partner of BOHE Angel Fund, one of the first angel funds in China focusing on healthcare start-ups, which invests in biologics, drug discovery and diagnostics. Ms. Liu was also a founding Chair of BioVENTURE Fund Investment committee. Ms. Liu previously served as the first Chief Representative to set up the China operation of Perrigo. Earlier in her career, she had various positions in quality and business development at Capsugel, a division of Warner-Lambert later acquired by Pfizer. Ms. Liu graduated from China Pharmaceutical University with a master's degree in pharmaceutics in 1997 and Master of Management at Fudan University and Norwegian Management School BI in 2004. She is a licensed pharmacist. - Yuwen Liu 自2022年2月起担任Adagene Inc.的独立董事。Yuwen Liu 女士是生物技术、生物制药和医疗技术行业的主要倡导者，曾担任企业家、顾问和投资者20多年。2010年至2014年，Yuwen Liu 女士担任苏州工业园区生物技术发展有限公司BioBAY的董事长兼首席执行官，之后担任执行董事，将其打造成发展最快的生物技术集群之一，服务于400多家初创企业，包括BrightGene、Innovent和苏州桥根，她还在董事会任职。在此之前，Yuwen Liu 女士自2005年起在BioBay担任过多个职位。作为创新的坚定支持者，她还是博和天使基金的创始合伙人。博和天使基金是中国首批专注于医疗保健初创企业的天使基金之一，投资于生物制品、药物发现和诊断。Yuwen Liu 女士还是生物风险基金投资委员会的创始主席。Yuwen Liu 女士曾担任Perrigo在中国设立业务的首位首席代表。在职业生涯早期，她曾在华纳兰伯特旗下的Capsugel公司担任质量和业务发展方面的多个职位，后来被辉瑞收购。Yuwen Liu 女士于1997年毕业于中国药科大学，获得药剂学硕士学位，并于2004年在复旦大学和挪威管理学院获得管理硕士学位。她是一名持证药剂师。
- Yuwen Liu has served as our independent director since February 2022. Ms. Liu is a leading advocate for the biotechnology, biopharmaceutical and medical technology industries, with over 20 years as an entrepreneur, advisor and investor. From 2010 to 2014 Ms. Liu was Chair and CEO, followed by executive director, of Suzhou Industrial Park Biotech Development Co. Ltd. BioBAY, building it into one of the fastest growing biotech clusters serving over 400 start-ups, including BrightGene, Innovent, and Qiagen Suzhou, where she also served on the boards of directors. Prior to that, Ms. Liu served various positions at BioBay since 2005. As a strong supporter of innovation, she was also a founding partner of BOHE Angel Fund, one of the first angel funds in China focusing on healthcare start-ups, which invests in biologics, drug discovery and diagnostics. Ms. Liu was also a founding Chair of BioVENTURE Fund Investment committee. Ms. Liu previously served as the first Chief Representative to set up the China operation of Perrigo. Earlier in her career, she had various positions in quality and business development at Capsugel, a division of Warner-Lambert later acquired by Pfizer. Ms. Liu graduated from China Pharmaceutical University with a master's degree in pharmaceutics in 1997 and Master of Management at Fudan University and Norwegian Management School BI in 2004. She is a licensed pharmacist.
高管简历
中英对照 | 中文 | 英文- Peter Luo
Peter Luo是天演药业的联合创始人，自2011年11月起担任天演药业的首席执行官，自2018年2月起担任董事会主席。Luo博士于1998年7月至2000年8月在Xencor（Nasdaq：XNCR）担任计算蛋白质设计和蛋白质实验室的第一位首席科学家。2000年9月Luo博士创立了Abmaxis Inc.，并担任其联合创始人、首席技术官、总裁和董事，2006年5月Luo博士领导默克制药公司（NYSE：MRK）收购了Abmaxis Inc.，之后Luo博士在默克担任生物技术总监，并在整个职业生涯中担任默克制药子公司Abmaxis的首席技术官，Luo博士还领导了与多个全球合作伙伴的合作和战略伙伴关系方面的业务发展努力，Luo博士于1986年获得北京大学技术物理应用化学学士学位，1989年获得中国科学院高能物理研究所应用物理硕士学位，1995年获得芝加哥大学化学博士学位。Luo博士还于1998年在斯坦福大学完成了蛋白质折叠方面的博士后研究。Luo博士的配偶是Xiaohong（Kristine）她是天演药业的高级副总裁，临床运营负责人。
Peter Luo is Adagene Inc. Co-Founder and has served as Adagene Inc. Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor Nasdaq: XNCR from July 1998 to August 2000. In September 2000 Dr. Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006 Dr. Luo led the acquisition of Abmaxis Inc. by Merck & Co. NYSE: MRK, after which Dr. Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr. Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr. Luo received his bachelor's degree in applied chemistry in technical physics from Peking University in 1986 master's degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989 and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998. Dr. Luo's spouse is Xiaohong Kristine She who is Adagene Inc. Senior Vice President, Head of Clinical Operations.- Peter Luo是天演药业的联合创始人，自2011年11月起担任天演药业的首席执行官，自2018年2月起担任董事会主席。Luo博士于1998年7月至2000年8月在Xencor（Nasdaq：XNCR）担任计算蛋白质设计和蛋白质实验室的第一位首席科学家。2000年9月Luo博士创立了Abmaxis Inc.，并担任其联合创始人、首席技术官、总裁和董事，2006年5月Luo博士领导默克制药公司（NYSE：MRK）收购了Abmaxis Inc.，之后Luo博士在默克担任生物技术总监，并在整个职业生涯中担任默克制药子公司Abmaxis的首席技术官，Luo博士还领导了与多个全球合作伙伴的合作和战略伙伴关系方面的业务发展努力，Luo博士于1986年获得北京大学技术物理应用化学学士学位，1989年获得中国科学院高能物理研究所应用物理硕士学位，1995年获得芝加哥大学化学博士学位。Luo博士还于1998年在斯坦福大学完成了蛋白质折叠方面的博士后研究。Luo博士的配偶是Xiaohong（Kristine）她是天演药业的高级副总裁，临床运营负责人。
- Peter Luo is Adagene Inc. Co-Founder and has served as Adagene Inc. Chief Executive Officer since November 2011 and Chairman of the Board of the Directors since February 2018. Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor Nasdaq: XNCR from July 1998 to August 2000. In September 2000 Dr. Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May 2006 Dr. Luo led the acquisition of Abmaxis Inc. by Merck & Co. NYSE: MRK, after which Dr. Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck & Co. Throughout his career, Dr. Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr. Luo received his bachelor's degree in applied chemistry in technical physics from Peking University in 1986 master's degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989 and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr. Luo also completed his postdoctoral research in protein folding at Stanford University in 1998. Dr. Luo's spouse is Xiaohong Kristine She who is Adagene Inc. Senior Vice President, Head of Clinical Operations.
- Fangyong Du
Fangyong Du于2012年1月作为技术开发的副先例加入天演药业，并自2019年5月起担任天演药业的首席技术官。Du博士在生物研究和发现行业有超过20年的经验，并在《自然》、《科学》等全球知名科学期刊发表过多篇同行评议文章，Du博士于2009年10月至2010年7月就职于Affomix，2010年7月至2012年1月就职于Illumina （NASDAQ：ILMN），后于2012年1月加入公司担任技术开发副总裁，Du博士分别于1991年和1994年获得北京大学生理学和生物物理学学士学位和硕士学位，2001年获加州理工学院生物学博士学位。Du博士还于2007年完成了耶鲁大学的博士后研究。
Fangyong Du joined us as Vice Precedent of Technology Development in January 2012 and has served as our Chief Technology Officer since May 2019. Dr. Du has over 20 years of experience in biological research and discovery industry, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. Dr. Du worked at Affomix from October 2009 to July 2010 and Illumina Nasdaq: ILMN from July 2010 to January 2012 and then joined the Company in January 2012 as the Vice President of Technology Development. Dr. Du received his bachelor's degree and master's degree in physiology and biophysics in 1991 and 1994 respectively, from Peking University, and his Ph.D. degree in biology from the California Institute of Technology in 2001. Dr. Du also completed his postdoctoral research from Yale University in 2007.- Fangyong Du于2012年1月作为技术开发的副先例加入天演药业，并自2019年5月起担任天演药业的首席技术官。Du博士在生物研究和发现行业有超过20年的经验，并在《自然》、《科学》等全球知名科学期刊发表过多篇同行评议文章，Du博士于2009年10月至2010年7月就职于Affomix，2010年7月至2012年1月就职于Illumina （NASDAQ：ILMN），后于2012年1月加入公司担任技术开发副总裁，Du博士分别于1991年和1994年获得北京大学生理学和生物物理学学士学位和硕士学位，2001年获加州理工学院生物学博士学位。Du博士还于2007年完成了耶鲁大学的博士后研究。
- Fangyong Du joined us as Vice Precedent of Technology Development in January 2012 and has served as our Chief Technology Officer since May 2019. Dr. Du has over 20 years of experience in biological research and discovery industry, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. Dr. Du worked at Affomix from October 2009 to July 2010 and Illumina Nasdaq: ILMN from July 2010 to January 2012 and then joined the Company in January 2012 as the Vice President of Technology Development. Dr. Du received his bachelor's degree and master's degree in physiology and biophysics in 1991 and 1994 respectively, from Peking University, and his Ph.D. degree in biology from the California Institute of Technology in 2001. Dr. Du also completed his postdoctoral research from Yale University in 2007.
- JC Xu
JC Xu自2020年8月起担任天演药业的首席科学官。Xu博士拥有超过20年的肿瘤药物发现和开发经验，在美国生物制药行业拥有超过四年的业务开发、战略和运营经验，在加入Adagene之前，Xu博士曾于2017年至2020年在Celgene Now BMS担任研发中国战略负责人。在此之前，Xu博士于2012年至2017年在Celgene Quanticel Research担任战略与运营总监，在Quanticel Pharmaceuticals担任生物学总监。在Quanticel之前，Xu博士曾在辉瑞、安进、Corixa等多家生物制药公司担任领导职务，Xu博士1987年在北京医科大学现北京大学健康科学中心获得医学博士学位，1993年在伯明翰阿拉巴马大学获得免疫学博士学位。她于1996年完成了在DNAX研究所（现在的默克帕洛阿尔托）的博士后培训。她是一位发明家，拥有120多项已授权和正在申请的专利，并在同行评审的期刊上发表了50多篇文章。
JC Xu has served as our Chief Scientific Officer since August 2020. Dr. Xu has more than 20 years of experience in oncology drug discovery and development, and more than four years of experience in business development, strategy, and operations in the biopharmaceutical industry in the United States. Prior to joining Adagene, Dr. Xu was head of R&ED China Strategy at Celgene now BMS from 2017 to 2020. Prior to that, Dr. Xu was Director of Strategy & Operations at Celgene Quanticel Research and Director of Biology at Quanticel Pharmaceuticals from 2012 to 2017. Prior to Quanticel, Dr. Xu worked in leadership roles at a number of biopharmaceutical companies, including Pfizer, Amgen, and Corixa.Dr. Xu received her M.D. degree from Beijing Medical University now Peking University Health Science Center in 1987 and her Ph.D. degree in Immunology from University of Alabama at Birmingham in 1993. She completed her post-doctoral training at DNAX Research Institute now Merck Palo Alto in 1996. She is an inventor of more than 120 issued and pending patents and has published more than 50 articles in peer-reviewed journals.- JC Xu自2020年8月起担任天演药业的首席科学官。Xu博士拥有超过20年的肿瘤药物发现和开发经验，在美国生物制药行业拥有超过四年的业务开发、战略和运营经验，在加入Adagene之前，Xu博士曾于2017年至2020年在Celgene Now BMS担任研发中国战略负责人。在此之前，Xu博士于2012年至2017年在Celgene Quanticel Research担任战略与运营总监，在Quanticel Pharmaceuticals担任生物学总监。在Quanticel之前，Xu博士曾在辉瑞、安进、Corixa等多家生物制药公司担任领导职务，Xu博士1987年在北京医科大学现北京大学健康科学中心获得医学博士学位，1993年在伯明翰阿拉巴马大学获得免疫学博士学位。她于1996年完成了在DNAX研究所（现在的默克帕洛阿尔托）的博士后培训。她是一位发明家，拥有120多项已授权和正在申请的专利，并在同行评审的期刊上发表了50多篇文章。
- JC Xu has served as our Chief Scientific Officer since August 2020. Dr. Xu has more than 20 years of experience in oncology drug discovery and development, and more than four years of experience in business development, strategy, and operations in the biopharmaceutical industry in the United States. Prior to joining Adagene, Dr. Xu was head of R&ED China Strategy at Celgene now BMS from 2017 to 2020. Prior to that, Dr. Xu was Director of Strategy & Operations at Celgene Quanticel Research and Director of Biology at Quanticel Pharmaceuticals from 2012 to 2017. Prior to Quanticel, Dr. Xu worked in leadership roles at a number of biopharmaceutical companies, including Pfizer, Amgen, and Corixa.Dr. Xu received her M.D. degree from Beijing Medical University now Peking University Health Science Center in 1987 and her Ph.D. degree in Immunology from University of Alabama at Birmingham in 1993. She completed her post-doctoral training at DNAX Research Institute now Merck Palo Alto in 1996. She is an inventor of more than 120 issued and pending patents and has published more than 50 articles in peer-reviewed journals.
- Qinghai Zhao
Qinghai Zhao自2020年10月起担任天演药业的首席制造官。Zhao博士拥有超过25年的蛋白质治疗开发和从早期IND到商业备案定义产品开发战略的经验，在加入Adagene之前，Zhao博士曾于2017年至2020年10月在Forty Seven Inc.（NASDAQ：FTSV）担任技术开发和制造副总裁。在此之前，Zhao博士于2016年至2017年在AnaptysBio（NASDAQ：ANAB）担任CMC/Manufacturing副总裁。在AnaptysBio之前，Zhao博士曾于2014年至2016年在NGM生物制药公司担任执行董事和CMC负责人。Zhao博士还于2001年至2014年在美国人类基因组科学公司、Cogenesys公司和Teva生物制药公司担任过各种职务。Zhao博士于1982年获上海化工学院（现华东科技大学）学士学位，1986年获上海医科大学（现与复旦大学合并）硕士学位，1998年获乌普萨拉大学博士学位。
Qinghai Zhao has served as our Chief Manufacturing Officer since October 2020. Dr. Zhao has more than 25 years of experience in protein therapeutics development and defining product development strategy from early stage IND through commercial filing. Prior to joining Adagene, Dr. Zhao was Vice President of Technical Development and Manufacturing at Forty Seven Inc. NASDAQ:FTSV from 2017 to October 2020. Prior to that, Dr. Zhao was vice president of CMC/ Manufacturing at AnaptysBio NASDAQ:ANAB from 2016 to 2017. Prior to AnaptysBio, Dr. Zhao worked as an Executive Director and the Head of CMC at NGM Biopharmaceuticals from 2014 to 2016. Dr. Zhao also held various positions at Human Genome Sciences, Inc., Cogenesys and Teva Biopharmaceuticals USA from 2001 to 2014. Dr. Zhao received his bachelor's degree from Shanghai Chemical Engineering Institute now East China University of Sciences and Technology in 1982 master's degree from Shanghai Medical University (now merged with Fudan University) in 1986 and Ph.D. degree from University of Uppsala in 1998.- Qinghai Zhao自2020年10月起担任天演药业的首席制造官。Zhao博士拥有超过25年的蛋白质治疗开发和从早期IND到商业备案定义产品开发战略的经验，在加入Adagene之前，Zhao博士曾于2017年至2020年10月在Forty Seven Inc.（NASDAQ：FTSV）担任技术开发和制造副总裁。在此之前，Zhao博士于2016年至2017年在AnaptysBio（NASDAQ：ANAB）担任CMC/Manufacturing副总裁。在AnaptysBio之前，Zhao博士曾于2014年至2016年在NGM生物制药公司担任执行董事和CMC负责人。Zhao博士还于2001年至2014年在美国人类基因组科学公司、Cogenesys公司和Teva生物制药公司担任过各种职务。Zhao博士于1982年获上海化工学院（现华东科技大学）学士学位，1986年获上海医科大学（现与复旦大学合并）硕士学位，1998年获乌普萨拉大学博士学位。
- Qinghai Zhao has served as our Chief Manufacturing Officer since October 2020. Dr. Zhao has more than 25 years of experience in protein therapeutics development and defining product development strategy from early stage IND through commercial filing. Prior to joining Adagene, Dr. Zhao was Vice President of Technical Development and Manufacturing at Forty Seven Inc. NASDAQ:FTSV from 2017 to October 2020. Prior to that, Dr. Zhao was vice president of CMC/ Manufacturing at AnaptysBio NASDAQ:ANAB from 2016 to 2017. Prior to AnaptysBio, Dr. Zhao worked as an Executive Director and the Head of CMC at NGM Biopharmaceuticals from 2014 to 2016. Dr. Zhao also held various positions at Human Genome Sciences, Inc., Cogenesys and Teva Biopharmaceuticals USA from 2001 to 2014. Dr. Zhao received his bachelor's degree from Shanghai Chemical Engineering Institute now East China University of Sciences and Technology in 1982 master's degree from Shanghai Medical University (now merged with Fudan University) in 1986 and Ph.D. degree from University of Uppsala in 1998.
- Man Kin Tam
Man Kin Tam自2019年9月起担任天演药业的首席财务官，并将在天演药业有关F-1表格的注册声明生效后立即担任天演药业的董事。Man Kin Tam先生在亚太地区拥有超过20年的金融和银行业管理经验，Man Kin Tam先生于1999年至2010年在汇丰银行和摩根大通银行（N.A。）工作。Tam先生于2010年4月至2015年10月期间担任Mineralogy Pty Limited项目总监及Resourcehouse Limited财务总监。2015年10月至2019年8月，Tam先生连续担任中国再生医学国际有限公司（港交所：8158），Beijing Gas Blue Sky Holdings Limited（港交所代码：6828），Agentus Therapeutics，Inc.的首席财务官，Tam先生为澳洲会计师公会会员，美国会计师公会及香港会计师公会会员，亦为CFA及FRM特许持有人。他于1997年在奥克兰大学获得土木与资源工程学士学位，2001年在莫纳什大学获得会计学硕士学位，2005年在西安大略大学获得工商管理硕士学位。
Man Kin Tam has served as our Chief Financial Officer since September 2019 and our director since February 2021. Mr. Tam has over 20 years of management experience in finance and banking across the Asia-Pacific region. Mr. Tam worked in HSBC and J.P. Morgan Chase Bank, N.A. from 1999 to 2010. Mr. Tam served as project director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited from April 2010 to October 2015. From October 2015 to August 2019 Mr. Tam consecutively served as the Chief Financial Officer of China Regenerative Medicine International Limited HKEx: 8158 Beijing Gas Blue Sky Holdings Limited HKEx: 6828 and AgenTus Therapeutics, Inc. Mr. Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder. He received his bachelor's degree in civil & resources engineering from the University of Auckland in 1997 master's degree in practising accounting from Monash University in 2001 and an Executive Master of Business Administration degree from the University of Western Ontario in 2005.- Man Kin Tam自2019年9月起担任天演药业的首席财务官，并将在天演药业有关F-1表格的注册声明生效后立即担任天演药业的董事。Man Kin Tam先生在亚太地区拥有超过20年的金融和银行业管理经验，Man Kin Tam先生于1999年至2010年在汇丰银行和摩根大通银行（N.A。）工作。Tam先生于2010年4月至2015年10月期间担任Mineralogy Pty Limited项目总监及Resourcehouse Limited财务总监。2015年10月至2019年8月，Tam先生连续担任中国再生医学国际有限公司（港交所：8158），Beijing Gas Blue Sky Holdings Limited（港交所代码：6828），Agentus Therapeutics，Inc.的首席财务官，Tam先生为澳洲会计师公会会员，美国会计师公会及香港会计师公会会员，亦为CFA及FRM特许持有人。他于1997年在奥克兰大学获得土木与资源工程学士学位，2001年在莫纳什大学获得会计学硕士学位，2005年在西安大略大学获得工商管理硕士学位。
- Man Kin Tam has served as our Chief Financial Officer since September 2019 and our director since February 2021. Mr. Tam has over 20 years of management experience in finance and banking across the Asia-Pacific region. Mr. Tam worked in HSBC and J.P. Morgan Chase Bank, N.A. from 1999 to 2010. Mr. Tam served as project director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited from April 2010 to October 2015. From October 2015 to August 2019 Mr. Tam consecutively served as the Chief Financial Officer of China Regenerative Medicine International Limited HKEx: 8158 Beijing Gas Blue Sky Holdings Limited HKEx: 6828 and AgenTus Therapeutics, Inc. Mr. Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder. He received his bachelor's degree in civil & resources engineering from the University of Auckland in 1997 master's degree in practising accounting from Monash University in 2001 and an Executive Master of Business Administration degree from the University of Western Ontario in 2005.
- Yu Ren
Yu Ren自2021年1月起担任天演药业的首席战略和企业发展官。在加入天演药业之前，任博士曾在默克公司担任过多个职位。纽约证券交易所：MRK。他曾在投资组合管理和全球临床开发财务部工作，负责KEYTRUDA开发和促进KEYTRUDA临床试验优先化的财务/战略规划。他还曾在默克公司战略办公室从事企业战略方面的工作，并在默克公司业务发展部从事各种业务发展事务。在回到默克公司之前，任博士曾于2009年至2010年担任Quintiles/IQVIA Consulting的首席顾问。从2001年到2006年，任博士在默克研究实验室从事从发现到早期临床开发的药物研究与开发。2001年获美国明尼苏达大学化学博士学位，1996年获北京大学化学学士学位。
Yu Ren has served as our Chief Strategy and Corporate Development Officer since January 2021. Dr. Ren has tendered his resignation and will depart from our Company in early June 2022. Prior to joining us, Dr. Ren held various positions at Merck & Co., Inc. NYSE: MRK. He had previously worked at Portfolio Management & Global Clinical Development Finance responsible for financial / strategic planning on KEYTRUDA® development and facilitation of KEYTRUDA® clinical trials prioritization. He also worked at Merck Corporate Strategy Office on enterprise strategy and at Merck Corporate Business Development on a variety of business development transactions. Before returning to Merck, Dr. Ren served as a principal consultant at Quintiles/IQVIA Consulting from 2009 to 2010. Dr. Ren gained extensive consulting experience at McKinsey & Company from 2007 to 2009. Dr. Ren started his professional career at Merck Research Lab working on Pharmaceutical Research & Development from discovery to early clinical development from 2001 to 2006. Dr. Ren received his Ph.D. in Chemistry from University of Minnesota in 2001 and bachelor's degree in Chemistry from Peking University in 1996.- Yu Ren自2021年1月起担任天演药业的首席战略和企业发展官。在加入天演药业之前，任博士曾在默克公司担任过多个职位。纽约证券交易所：MRK。他曾在投资组合管理和全球临床开发财务部工作，负责KEYTRUDA开发和促进KEYTRUDA临床试验优先化的财务/战略规划。他还曾在默克公司战略办公室从事企业战略方面的工作，并在默克公司业务发展部从事各种业务发展事务。在回到默克公司之前，任博士曾于2009年至2010年担任Quintiles/IQVIA Consulting的首席顾问。从2001年到2006年，任博士在默克研究实验室从事从发现到早期临床开发的药物研究与开发。2001年获美国明尼苏达大学化学博士学位，1996年获北京大学化学学士学位。
- Yu Ren has served as our Chief Strategy and Corporate Development Officer since January 2021. Dr. Ren has tendered his resignation and will depart from our Company in early June 2022. Prior to joining us, Dr. Ren held various positions at Merck & Co., Inc. NYSE: MRK. He had previously worked at Portfolio Management & Global Clinical Development Finance responsible for financial / strategic planning on KEYTRUDA® development and facilitation of KEYTRUDA® clinical trials prioritization. He also worked at Merck Corporate Strategy Office on enterprise strategy and at Merck Corporate Business Development on a variety of business development transactions. Before returning to Merck, Dr. Ren served as a principal consultant at Quintiles/IQVIA Consulting from 2009 to 2010. Dr. Ren gained extensive consulting experience at McKinsey & Company from 2007 to 2009. Dr. Ren started his professional career at Merck Research Lab working on Pharmaceutical Research & Development from discovery to early clinical development from 2001 to 2006. Dr. Ren received his Ph.D. in Chemistry from University of Minnesota in 2001 and bachelor's degree in Chemistry from Peking University in 1996.
- Chunfang Gu
Chunfang Gu 于 2017 年 9 月加入 Adagene，担任财务高级总监。 Vicky 向首席财务官汇报，管理 Adagene Inc. 的财务团队，在 Adagene Inc. 的资本市场和筹资交易中发挥关键作用，并协助建立 Adagene Inc. 的员工激励计划。 Vicky 拥有超过 17 拥有多年财务管理经验，曾接触过审计公司和跨国公司，包括 Sulzer Pumps、Bluescope Steel 和 Mercury Marine。 Vicky 在财务报告、预算和成本分析、内部控制和相关合规、税务以及项目管理方面拥有丰富的经验。 Vicky 于 2016 年获得厦门大学工商管理硕士学位，并于 2003 年获得天津商业大学会计学学士学位。
Chunfang Gu joined Adagene in September 2017 and serves as Senior Director of Finance. Reporting to the Chief Financial Officer, Vicky manages Adagene Inc.'s finance team, plays a key role in Adagene Inc.'s capital markets and fund-raising transactions and assisted to establish the employee incentive plans of Adagene Inc. Vicky has over 17 years of experience in financial management with exposure to audit firms and multinational corporations including Sulzer Pumps, Bluescope Steel and Mercury Marine. Vicky has rich experience on financial reporting, budgeting and cost analysis, internal control and related compliance, taxation, as well as project management. Vicky received her Master of Business Administration degree from Xiamen University in 2016 and bachelor's degree in accounting from Tianjin University of Commerce in 2003.- Chunfang Gu 于 2017 年 9 月加入 Adagene，担任财务高级总监。 Vicky 向首席财务官汇报，管理 Adagene Inc. 的财务团队，在 Adagene Inc. 的资本市场和筹资交易中发挥关键作用，并协助建立 Adagene Inc. 的员工激励计划。 Vicky 拥有超过 17 拥有多年财务管理经验，曾接触过审计公司和跨国公司，包括 Sulzer Pumps、Bluescope Steel 和 Mercury Marine。 Vicky 在财务报告、预算和成本分析、内部控制和相关合规、税务以及项目管理方面拥有丰富的经验。 Vicky 于 2016 年获得厦门大学工商管理硕士学位，并于 2003 年获得天津商业大学会计学学士学位。
- Chunfang Gu joined Adagene in September 2017 and serves as Senior Director of Finance. Reporting to the Chief Financial Officer, Vicky manages Adagene Inc.'s finance team, plays a key role in Adagene Inc.'s capital markets and fund-raising transactions and assisted to establish the employee incentive plans of Adagene Inc. Vicky has over 17 years of experience in financial management with exposure to audit firms and multinational corporations including Sulzer Pumps, Bluescope Steel and Mercury Marine. Vicky has rich experience on financial reporting, budgeting and cost analysis, internal control and related compliance, taxation, as well as project management. Vicky received her Master of Business Administration degree from Xiamen University in 2016 and bachelor's degree in accounting from Tianjin University of Commerce in 2003.
- Ling Zhou
Ling Zhou 自 2019 年 10 月起担任Adagene Inc.的人力资源高级总监。在加入 Adagene 之前，Zhou 女士曾担任 Tekni-Plex 的亚太区人力资源总监，从 2010 年 5 月到 2019 年 8 月。2004 年 10 月至 2010 年 5 月，Zhou 女士担任辉瑞旗下苏州胶囊有限公司的人力资源主管，负责所有人力资源职能和人员培训。 Zhou 女士于2003年获得中南民族大学法学学士学位。她是DDI认证培训师。
Ling Zhou has served as our Senior Director of Human Resources since October 2019. Before joining Adagene, Ms. Zhou served as the HR director of Asia Pacific at Tekni-Plex, where she was responsible for strategic HR initiatives and business support from May 2010 to August 2019. Between October 2004 and May 2010 Ms. Zhou served as the HR supervisor at Suzhou Capsugel Ltd., a division of Pfizer, where she was responsible for all HR functions and personnel training. Ms. Zhou received her bachelor's degree in law from South-Central University for Nationalities in 2003. She is a DDI Certified Trainer.- Ling Zhou 自 2019 年 10 月起担任Adagene Inc.的人力资源高级总监。在加入 Adagene 之前，Zhou 女士曾担任 Tekni-Plex 的亚太区人力资源总监，从 2010 年 5 月到 2019 年 8 月。2004 年 10 月至 2010 年 5 月，Zhou 女士担任辉瑞旗下苏州胶囊有限公司的人力资源主管，负责所有人力资源职能和人员培训。 Zhou 女士于2003年获得中南民族大学法学学士学位。她是DDI认证培训师。
- Ling Zhou has served as our Senior Director of Human Resources since October 2019. Before joining Adagene, Ms. Zhou served as the HR director of Asia Pacific at Tekni-Plex, where she was responsible for strategic HR initiatives and business support from May 2010 to August 2019. Between October 2004 and May 2010 Ms. Zhou served as the HR supervisor at Suzhou Capsugel Ltd., a division of Pfizer, where she was responsible for all HR functions and personnel training. Ms. Zhou received her bachelor's degree in law from South-Central University for Nationalities in 2003. She is a DDI Certified Trainer.